Quince Therapeutics (QNCX) “announced the presentation of two posters at the 2024 International Congress for Ataxia Research (ICAR) of data from its prior Phase 3 ATTeST (Ataxia-Telangiectasia Trial with the EryDex SysTem; #IEDAT-02-2015/NCT02770807) clinical trial of the company’s lead asset, EryDex, for the treatment of Ataxia-Telangiectasia (A-T).
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio